2008-12-18 18:49:03 -
Regulatory News:
The board of directors in Q-Med AB has received from Lyftet Holding B.V. a request for summoning of an extra shareholders' meeting for election of a new board of directors, subject to the limitations set out in Q-Med's articles of association.
As soon as a date for a shareholders' meeting has been settled, January 2, 2009 at the latest, a press release will be distributed and a notice will be published in Svenska Dagbladet, Upsala Nya Tidning and Post- och Inrikes Tidningar (Swedish Official Gazette). Information will also be available on the corporate web site.
Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and
sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHA", for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: Restylane® for filling lines and folds, contouring and creating volume in the face, Macrolane" for body contouring, Durolane" for the treatment of osteoarthritis of the hip and knee joints, Deflux® for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and Solesta" for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.
Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882.
Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail:
info@q-med.com. Web: www.q-med.com.
In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc.
This information was brought to you by Cision
www.cisionwire.com
Q-Med AB
Pia Rudengren, Chairman of the Board
Mobile: +46 (0)706 242041 or +46 (0)768 161490
